- Open Access
Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG
- Ingmar JJ Claes†1, 2,
- Marijke E Segers†1, 2,
- Tine LA Verhoeven1,
- Michiel Dusselier3,
- Bert F Sels3,
- Sigrid CJ De Keersmaecker1,
- Jos Vanderleyden1 and
- Sarah Lebeer1, 2Email author
© Claes et al.; licensee BioMed Central Ltd. 2012
- Received: 4 October 2012
- Accepted: 5 December 2012
- Published: 15 December 2012
Probiotic bacteria are increasingly used as immunomodulatory agents. Yet detailed molecular knowledge on the immunomodulatory molecules of these bacteria is lagging behind. Lipoteichoic acid (LTA) is considered a major microbe-associated molecular pattern (MAMP) of Gram-positive bacteria. However, many details and quantitative data on its immune signalling capacity are still unknown, especially in beneficial bacteria. Recently, we have demonstrated that a dltD mutant of the model probiotic Lactobacillus rhamnosus GG (LGG), having modified LTA molecules, has an enhanced probiotic efficacy in a DSS-induced colitis model as compared to wild-type.
In this study, the importance of D-alanylated and acylated LTA for the pro-inflammatory activity of LGG was studied in vitro. Purified native LTA of LGG wild-type exhibited a concentration-dependent activation of NF-κB signalling in HEK293T cells after interaction with TLR2/6, but not with TLR2 alone. Chemical deacylation of LTA interfered with the TLR2/6 interaction, while a moderate effect was observed with chemical dealanylation. Similarly, the dltD mutant of LGG exhibited a significantly reduced capacity to activate TLR2/6-dependent NF-κB signalling in a HEK293T reporter cell line compared to wild-type. In addition, the dltD mutant of LGG showed a reduced induction of mRNA of the chemokine IL-8 in the Caco-2 epithelial cell line compared to wild-type. Experiments with highly purified LTA of LGG confirmed that LTA is a crucial factor for IL-8 mRNA induction in Caco-2 epithelial cells. Chemical dealanylation and deacylation reduced IL-8 mRNA expression.
Taken together, our results indicate that LTA of LGG is a crucial MAMP with pro-inflammatory activities such as IL-8 induction in intestinal epithelial cells and NF-κB induction in HEK293T cells via TLR2/6 interaction. The lipid chains of LGG LTA are needed for these activities, while also the D-alanine substituents are important, especially for IL-8 induction in Caco-2 cells.
- Lipoteichoic acid
The immunomodulatory potential of probiotic bacteria is of increasing interest for prophylactic and therapeutic options in various complex disorders, ranging from diarrhea to allergy. However, clinical and intervention studies with probiotics are not universally effective. For instance, the well-known probiotic Lactobacillus rhamnosus GG (LGG) shows promising results in the prevention of atopic disease[1–3], prevention and relief of diarrhea and prevention of respiratory tract infections in children, while the results in Crohn’s disease are less promising[6–8]. Clearly, the mode and timing of delivery and severity of the conditions are important factors in determining probiotic efficacy. To select the optimal strain for each application, detailed molecular knowledge would be of great help. Many immunomodulatory molecules of bacteria are microbe-associated molecular patterns or MAMPs that can interact with pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). PRRs expressed on host cells such as intestinal epithelial cells (IECs) and dendritic cells (DCs) in the gastro-intestinal tract appear to be especially crucial for probiotic-host interactions. The interaction between a MAMP and a PRR on host cells results in the induction of signalling cascades that mount a molecular response. This response can include the production of pro- or anti-inflammatory cytokines and chemokines, antimicrobial molecules and cytoprotective factors.
Many MAMPs are surface located molecules, such as lipopolysaccharides interacting with TLR4/MD2 and flagellin interacting with TLR5. Lipoteichoic acid (LTA) is a widely studied MAMP of the low G+C subdivision of the Gram-positive bacteria such as the Firmicutes. LTA is an amphiphilic molecule of which the hydrophilic region is generally composed of a 1,3-phosphodiester-linked polymer of glycerol-phosphate or ribitol-phosphate variously substituted with D-alanine or sugars. The hydrophobic region is a glycolipid, often Glc(β1-6)Glc(β1-3)diacylglycerol. LTA of several pathogens such as Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae has been shown to trigger the production of pro-inflammatory cytokines, nitric oxide (NO) and other pro-inflammatory mediators in various cell types[10, 11]. Similar to LPS, LTA appears to be an important endotoxin capable of causing sepsis. However, whereas LPS is active in the nanomolar range, biological activities of LTA are mostly observed in the micromolar range. Moreover, the activity of LTA is often debated due to problems with contaminants such as lipoproteins and loss of bio-active residues during isolation and purification. Some studies have indicated that TLR2 is an important PRR for pathogenic LTA of Streptococcus pneumoniae and Staphylococcus aureus, but generally without detailed mechanistic insights.
Recently, LTA molecules of probiotic lactobacilli have gained interest as important immune modulators based on studies with LTA mutants showing enhanced efficacy in experimental colitis models. We observed previously that LGG wild-type can aggravate colitic symptoms in a DSS-induced colitis model in mice, suggesting that pro-inflammatory molecules of LGG itself can trigger an enhanced inflammatory response in certain conditions such as in severely progressed colitis. In contrast to LGG wild-type, adding the dltD mutant of LGG seemed to improve colitic symptoms compared to the PBS control. This dltD mutant was previously shown to lack D-Ala on its LTA, but also expresses a modified glycolipid anchor and a shorter polyglycerol-P chain. Similarly, a dlt mutant with modified D-alanylation of LTA was shown to have a higher anti-inflammatory potential in L. plantarum NCIMB8826, while LTA removal in L. acidophilus NCFM conferred improved anti-inflammatory properties in several mouse models for IBD. However, only very limited data exist on the structure-activity relationship of LTA of probiotic lactobacilli. In this study, we aimed to provide molecular insights in the biological activity of LTA of the widely used and model probiotic strain LGG, by investigating its potential pro-inflammatory activity and its interaction with PRRs in cell models.
Isolation and chemical characterization of native and modified LTA of LGG
NF-κB activation of LGG LTA by interaction with TLR2/6
Importance of D-Ala substituents and acyl chains for TLR2/6 interaction by LGG LTA
To establish a structure-activity relation of LTA of LGG in interaction with TLR2/6 as PRRs, experiments were performed with chemically deacylated and dealanylated LTA, i.e. mLTA1 and mLTA2 described above. Partially modified mLTA1 showed a similar signalling through TLR2/TLR6 as native LTA, while the more severely deacetylated and fully dealanylated mLTA2 proved ineffective in activating NF-κB (Figure4).
Interestingly, a similar trend was observed when investigating the interaction capacity of whole UV-irradiated bacterial cells. While LGG wild-type was able to significantly activate NF-κB signalling via TLR2/6 interaction, the dltD mutant, having modified LTA, significantly induced less NF-κB (Figure4).
IL-8 mRNA induction in intestinal epithelial cells by LGG LTA
In addition, we investigated the IL-8 mRNA induction capacity of LGG wild-type versus the dltD mutant. Compared to the negative control (DMEM), LGG wild-type significantly induced IL-8 mRNA, while the dltD mutant did not (Figure5B). Blocking experiments with anti-LTR2 antibodies confirmed the importance of TLR2 for IL-8 mRNA induction by LGG wild-type (data not shown).
In this study, we aimed to investigate the importance of the LTA structure of LGG in mediating pro-inflammatory effects in dedicated cell models. Hereto, we used highly purified native and chemically modified LTA of LGG. First, we showed that LGG LTA is able to activate NF-κB in HEK293T cells via interaction with the PRR couple TLR2/6. Importantly, this activity was not observed when the HEK293T cells were only transfected with TLR2, highlighting the importance of TLR6 as coreceptor for LGG LTA. This is in agreement with the PRRs of LTA molecules of S. aureus and group B streptococci, which were shown to interact with TLR2/6 and not TLR1/6. For lactobacilli, the pro-inflammatory potential of LTA of L. plantarum NCBIM8826 was shown to be TLR2 dependent using bone marrow cells isolated from TLR2+/+ and TLR2−/− mice. Experiments with LTA from L. casei and L. fermentum using HEK293T cells revealed that CD14 could only activate NF-κB when cotransfected with TLR2. Taken together, it seems that the pro-inflammatory character of LTA from different species is TLR2 dependent but needs coreceptors, such as TLR6 and/or CD14.
When we compared the activity of native with chemically modified LTA confirmed by NMR spectroscopy, i.e. mLTA1 (mild alkaline hydrolysis - partial removal of D-Ala) and mLTA2 (harsh alkaline hydrolysis - complete removal of D-Ala and partial acyl chain removal), D-alanylation does not appear to be crucial for TLR2/6 interaction. While a harsh chemical deacylation of 55% (mLTA2) completely abolished the NF-κB induction by LGG LTA, a severe chemical dealanylation of 72% (mLTA1) did not significantly affect this signalling. Our data confirm the essential role of the lipid part of LTA, as has been previously shown for other ligands in interaction with TLR2. Yet, they also suggest a modulatory role for the D-Ala substituents in signalling. This highlights the importance of structure-activity data for LTA of different species.
Subsequent experiments with the Caco-2 intestinal epithelial cells, a cell line that has been extensively used as a model for the intestinal barrier, indicate that LTA of LGG can indeed induce an inflammatory response, in this case a concentration-dependent increase in mRNA expression of the chemokine IL-8. Chemical dealanylation (mLTA1) was sufficient to significantly reduce IL-8 mRNA induction. These experiments suggest that the D-Ala substituents of LGG LTA are more important for IL-8 mRNA induction in Caco-2 cells than for NF-kB induction in HEK293T cells. This would be in agreement with the fact that full IL-8 mRNA induction in differentiated Caco-2 epithelial cells requires the interaction of LGG LTA with TLR2/6 and additional coreceptors interacting with the D-Ala substituents, which are not present in the less differentiated HEK293T cells. Furthermore, we could show in this study that the dltD mutant of LGG shows a significantly reduced pro-inflammatory capacity compared to wild-type, as assessed by TLR2/6-dependent NF-kB induction in HEK293T cells and IL-8 mRNA induction by Caco-2 cells. This is in agreement with its observed reduced pro-inflammatory and even enhanced anti-inflammatory and enhanced epithelial repair activity in vivo.
Due to pleiotropic effects of the dltD mutation, we were unable to isolate LTA from the dltD mutant that was sufficiently pure for immunomodulation experiments. Therefore, we are currently unable to answer the question as to whether the specific LTA structure of the dltD mutant as described in Perea Vélez et al., results in this reduced pro-inflammatory capacity. Nevertheless, the data for NMR characterized chemical dealanylated and deacylated LGG LTA confirm the importance of both structural features for its pro-inflammatory potential.
In conclusion, we have convincingly shown in this study that LTA of LGG is an important MAMP of LGG for interaction with TLR2/6. Moreover, LTA is an important factor in the induction of pro-inflammatory markers in the Caco-2 intestinal epithelial cell line. This activity of LTA needs to be taken into account when selecting the optimal application for LGG. For example, in a disease situation like active colitis, extra pro-inflammatory stimulation by LTA of probiotic bacteria would be undesirable. Although human application of genetically modified probiotics such as the dltD mutant of LGG is not an option, experiments with mutants and isolated compounds such as shown in this study highlight the importance of tailored applications. Screening or searching for probiotic strains with less pro-inflammatory LTA seems to be important for specific disease conditions with a general pro-inflammatory profile. On the other hand, for application of probiotic strains or purified LTA as adjuvants, more immunostimulatory characteristics could be more appropriate.
Bacterial strains, media and growth conditions
LGG and the dltD mutant (CMPG5540) were grown at 37°C in MRS medium (Difco) or AOAC medium (Difco) under static conditions.
Overnight LGG wild-type cell cultures were centrifuged for 30 min (4000 rpm, 4°C) and the white cell pellets were stored at −80°C. Highly purified LTA was isolated according to Morath et al.. In order to release LTA from the peptidoglycan matrix, the cells were disrupted mechanically by sonication. Hence, a defrosted aliquot of bacteria (ca. 40 g) was suspended in 80 mL of citrate buffer (0.1 M, pH = 4). The milky solution was placed in an ice bath and 4 subsequent sonication steps were accomplished (duty cycle = 50%, output > 50). To remove the contaminant lipophilic cell molecules from the LTA containing buffer solution, an extraction step with n-butanone was applied as described by Morath et al., as the classical extraction method with phenol-water at 68°C and subsequent dialysis was previously shown to partly desintegrate structure of the purified LTA.
The purification of LTA was accomplished by hydrophobic interaction chromatography (HIC) on an octyl-Sepharose CL-4B (GE Healthcare) packed in XK 16/60 column (GE Healthcare) using a linear gradient from 15% to 60% n-propanol in ammonium acetate (0.1 M, pH = 4.75). Hence, the lyophilized sample was suspended in 35 ml of chromatography start buffer (15% n-propanol in 0.1 M ammonium acetate, pH = 4.75) and centrifuged for 1 h (15000 rpm, 4°C). After sterilization by membrane filtration (0.2 μm), the supernatant was subjected to HIC.
The LTA containing fractions were identified by their phosphate content using the phosphomolybdenum test. Therefore, to 50 μL of each fraction 200 μL of an acid solution (2 M H2SO4/0.44 M HClO4) was added and the samples were incubated at 140°C for 2 h. Next, a reduction solution (ammonium heptamolybdate solution: ascorbine solution 9:1) was added to each sample. After 2 h of incubation at 50°C, 200 μL of each sample was transferred into a microtiter plate. Absorption was measured at 700 nm. The phosphate content was determined by comparison to a P standard.
The LTA-containing fractions were collected and lyophilized after freezing with liquid N2. The lyophilized fractions were suspended in ca. 10 mL milli-Q water and lyophilized once more.
Dealanylation of LTA was achieved by increasing the pH of the water phase after butanol extraction, and by stirring at pH ≈ 8.5 with Tris buffer at RT (25°C) for 24 h as described previously. Deacylation of LTA was performed at 37°C for 2 h with 0.1M NaOH. LPS contamination was assessed with that LAL assay (<0.1 EU/ml; QCL-1000; Lonza).
LTA structure analysis
Proton (1H) Nuclear magnetic resonance (NMR) spectra of the LTA samples were measured in 5 mm Norell tubes on a Bruker Avance II-plus 600 MHz spectrometer equipped with a TXI-5 probe at 298 K. Spectra were obtained using D2O as a solvent, with the residual solvent peak at 4.7 ppm. The data acquisition, post-processing and integrations were performed in Bruker Topspin 2.1 and 2.0. The length of the polyglycerophosphate backbone, the percentage of substitution of the second position of every glycerol with D-alanine, and the average chain length of the fatty acids in the membrane anchor were calculated using the appropriate integrated signals of the proton NMR spectra.
Immunomodulation assay with Caco-2 cells
Caco-2 cells were purchased from ATCC (Rockville, MD). Cells were routinely grown in 75-cm2 culture flasks under conditions of 37°C, 5% CO2, and 90% relative humidity. Dulbecco modified Eagle medium (DMEM)/F-12 (GibcoBRL) (1:1) supplemented with 10% fetal bovine serum (FBS; HyClone) was used as the culture medium. Cells were passaged every 3 days (at 70 to 80% confluency) at a split ratio of 1 to 7. Epithelial cells were plated at a density of 104 cells/cm2 in 12-well plates (Cellstar). Confluency was reached within 3 to 4 days after seeding, and monolayers were used for the experiments 5–7 days after seeding. Caco-2 cells were incubated with LGG wild type, the dltD mutant (107 CFU/ml) or LTA (at different concentrations) for 1.5 hours.
Analysis of cytokine mRNA levels by qRT-PCR
To determine cytokine mRNA levels by qRT-PCR, commercially available methodologies for performing total cellular RNA extraction (High pure RNA isolation kit, Roche), reverse transcription (SuperScript III first-strand Synthesis system, Invitrogen) and real-time DNA amplification (TaqMan Universal PCR Master Mix, Applied Biosystems) were applied. For real-time quantitative PCR (RT-qPCR) amplification, the StepOnePlus Real Time PCR system (Applied Biosystems, Lennik, Belgium) was used. All primers and probes were designed based on published sequences and chemically synthesized by Eurogentec (Seraing, Belgium). Purified plasmid DNA specific for each targeted cytokine gene served as cDNA plasmid standards and was used to quantify the respective cytokine in the test samples. The relative abundance of each mRNA species was measured by qPCR using 45 amplification cycles, with each cycle consisting of a denaturation step (94°C for 15 s) and a 1 min combined annealing-extension step (60°C). qPCR data are presented as a ratio of the mRNA level for cytokine genes over that of the housekeeping gene peptidylprolyl isomerase A (PPIA), one of the most stably expressed genes in Caco-2 cells.
Transient transfection of HEK293T cells and measurement of alkaline phosphatase activity
HEK293T cells (ATCC, Manassas, VA, USA) were cultured in DMEM/F-12 (GibcoBRL) (1:1) supplemented with 6% fetal bovine serum (FBS; HyClone) and 50μg/mL gentamycin in 5% CO2, 37°C, RH 90%. The cells (0.5 x 106 cells/mL) were seeded in 12-well plates. These cells were then transfected with either pNiFty-SEAP alone or in combination with pUNO1-hTLR2 or pDUO-hTLR6/TLR2 (Invivogen Inc., San Diego, USA) using branched polyethylenimine (MW ~ 25.000). Transfected cells were cultured for 24 h and then incubated with Pam2CSK4 (positive control from Invivogen), LTA, UV inactivated LGG or the dltD mutant for an additional 24 h. All experiments were performed at least two times. After incubation, NF-κB-induced secreted alkaline phosphatase (SEAP) activity was assessed using pNPP (p-nitrophynyl phosphate) at 1 mg/mL and measuring the OD at 405 nm.
Values are presented as mean ± SD. Difference were evaluated by the unpaired Student’s t test. A value of p ≤ 0.05 was considered to be significant.
At the time of experiments, SL was a postdoctoral researcher of the fund for scientific research (FWO) of Flanders, Belgium and MES and IJJC held a PhD grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT–Vlaanderen). MD acknowledges FWO (Grant 1.1.955.10N). Funding of this project at the K.U.Leuven was in part through the Fund for Scientific Research, Flanders (FWO) (Grant G.0236.07) and in part through TEKES (Finnish Funding Agency for Technology and Innovation) (Grant 201/08). The authors would like to especially thank A. Demuynck for providing us the highly purified LTA.
- Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001, 357 (9262): 1076-1079. 10.1016/S0140-6736(00)04259-8View ArticleGoogle Scholar
- Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet. 2003, 361 (9372): 1869-1871. 10.1016/S0140-6736(03)13490-3View ArticleGoogle Scholar
- Kalliomaki M, Salminen S, Poussa T, Isolauri E: Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2007, 119 (4): 1019-1021. 10.1016/j.jaci.2006.12.608View ArticleGoogle Scholar
- Guandalini S: Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011, 45 (Suppl): S149-S153.View ArticleGoogle Scholar
- Hojsak I, Abdovic S, Szajewska H, Milosevic M, Krznaric Z, Kolacek S: Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010, 125 (5): e1171-e1177. 10.1542/peds.2009-2568View ArticleGoogle Scholar
- Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, et al: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease. Inflamm Bowel Dis. 2005, 11 (9): 833-839.View ArticleGoogle Scholar
- Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002, 51 (3): 405-409. 10.1136/gut.51.3.405View ArticleGoogle Scholar
- Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC: Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004, 4: 5-, 10.1186/1471-230X-4-5View ArticleGoogle Scholar
- Lebeer S, Vanderleyden J, De Keersmaecker SC: Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol. 2010, 8 (3): 171-184. 10.1038/nrmicro2297View ArticleGoogle Scholar
- Neuhaus FC, Baddiley J: A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev. 2003, 67 (4): 686-723. 10.1128/MMBR.67.4.686-723.2003View ArticleGoogle Scholar
- Ginsburg I: Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis. 2002, 2 (3): 171-179. 10.1016/S1473-3099(02)00226-8View ArticleGoogle Scholar
- Hashimoto M, Tawaratsumida K, Kariya H, Kiyohara A, Suda Y, Krikae F, Kirikae T, Gotz F: Not lipoteichoic acid but lipoproteins appear to be the dominant immunobiologically active compounds in Staphylococcus aureus. J Immunol. 2006, 177 (5): 3162-3169.View ArticleGoogle Scholar
- Dessing MC, Schouten M, Draing C, Levi M, von Aulock S, van der Poll T: Role played by Toll-like receptors 2 and 4 in lipoteichoic acid-induced lung inflammation and coagulation. J Infect Dis. 2008, 197 (2): 245-252. 10.1086/524873View ArticleGoogle Scholar
- Nilsen NJ, Deininger S, Nonstad U, Skjeldal F, Husebye H, Rodionov D, von Aulock S, Hartung T, Lien E, Bakke O, et al: Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36. J Leukoc Biol. 2008, 84 (1): 280-291. 10.1189/jlb.0907656View ArticleGoogle Scholar
- Lebeer S, Claes IJ, Vanderleyden J: Anti-inflammatory potential of probiotics: lipoteichoic acid makes a difference. Trends Microbiol. 2012, 20 (1): 5-10. 10.1016/j.tim.2011.09.004View ArticleGoogle Scholar
- Claes IJ, Lebeer S, Shen C, Verhoeven TL, Dilissen E, De Hertogh G, Bullens DM, Ceuppens JL, Van Assche G, Vermeire S, et al: Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol. 2010, 162 (2): 306-314. 10.1111/j.1365-2249.2010.04228.xView ArticleGoogle Scholar
- Perea Vélez M, Verhoeven TL, Draing C, Von Aulock S, Pfitzenmaier M, Geyer A, Lambrichts I, Grangette C, Pot B, Vanderleyden J, et al: Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG. Appl Environ Microbiol. 2007, 73 (11): 3595-3604. 10.1128/AEM.02083-06View ArticleGoogle Scholar
- Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, Pot B, Hartung T, Hols P, Mercenier A: Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci USA. 2005, 102 (29): 10321-10326. 10.1073/pnas.0504084102View ArticleGoogle Scholar
- Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, Managlia E, Bere P, Sarraj B, Khan MW, Pakanati KC, et al: Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci USA. 2011, 108 (1): 4623-4630. 10.1073/pnas.1005066107View ArticleGoogle Scholar
- Morath S, Geyer A, Hartung T: Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J Exp Med. 2001, 193 (3): 393-397. 10.1084/jem.193.3.393View ArticleGoogle Scholar
- Finney SJ, Anning PB, Cao TV, Perretti M, Evans TW, Burke-Gaffney A: Butanol-extracted lipoteichoic acid induces in vivo leukocyte adhesion. Biochem Biophys Res Commun. 2007, 364 (4): 831-837. 10.1016/j.bbrc.2007.10.088View ArticleGoogle Scholar
- Lebeer S, Claes I, Tytgat HL, Verhoeven TL, Marien E, von Ossowski I, Reunanen J, Palva A, Vos WM, Keersmaecker SC, et al: Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012, 78 (1): 185-193. 10.1128/AEM.06192-11View ArticleGoogle Scholar
- Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, Muller A, Poyart C, Akira S, Berner R, et al: Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005, 174 (10): 6449-6455.View ArticleGoogle Scholar
- Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO: Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007, 130 (6): 1071-1082. 10.1016/j.cell.2007.09.008View ArticleGoogle Scholar
- Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F: The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol. 2005, 21 (1): 1-26. 10.1007/s10565-005-0085-6View ArticleGoogle Scholar
- Morath S, Geyer A, Spreitzer I, Hermann C, Hartung T: Structural decomposition and heterogeneity of commercial lipoteichoic acid preparations. Infect Immun. 2002, 70 (2): 938-944. 10.1128/IAI.70.2.938-944.2002View ArticleGoogle Scholar
- Schnitger H, Papenberg K, Ganse E, Czok R, Buecher T, Adam H: Chromatography of phosphorus-containing metabolities in a human liver biopsy specimen. Biochem Z. 1959, 332: 167-185.Google Scholar
- Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, et al: Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci. 2008, 35 (5): 383-396. 10.1016/j.ejps.2008.08.004View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.